IRIS Accounts Production v25.1.4.42 12965535 director 1.7.23 30.6.24 30.6.24 0 false true false false true false Ordinary 0.0100 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh129655352023-06-30129655352024-06-30129655352023-07-012024-06-30129655352022-06-30129655352022-07-012023-06-30129655352023-06-3012965535ns15:EnglandWales2023-07-012024-06-3012965535ns14:PoundSterling2023-07-012024-06-3012965535ns10:Director12023-07-012024-06-3012965535ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3012965535ns10:SmallEntities2023-07-012024-06-3012965535ns10:AuditExemptWithAccountantsReport2023-07-012024-06-3012965535ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3012965535ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3012965535ns10:FullAccounts2023-07-012024-06-3012965535ns10:OrdinaryShareClass12023-07-012024-06-3012965535ns10:RegisteredOffice2023-07-012024-06-3012965535ns5:CurrentFinancialInstruments2024-06-3012965535ns5:CurrentFinancialInstruments2023-06-3012965535ns5:ShareCapital2024-06-3012965535ns5:ShareCapital2023-06-3012965535ns5:RetainedEarningsAccumulatedLosses2024-06-3012965535ns5:RetainedEarningsAccumulatedLosses2023-06-3012965535ns5:PlantMachinery2023-06-3012965535ns5:PlantMachinery2023-07-012024-06-3012965535ns5:PlantMachinery2024-06-3012965535ns5:PlantMachinery2023-06-3012965535ns5:CostValuation2023-06-3012965535ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3012965535ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-3012965535ns10:OrdinaryShareClass12024-06-30
REGISTERED NUMBER: 12965535 (England and Wales)

























Unaudited Financial Statements

for the Year Ended 30 June 2024

for

Cantabio Pharmaceuticals Ltd

Cantabio Pharmaceuticals Ltd (Registered number: 12965535)






Contents of the Financial Statements
for the year ended 30 June 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Chartered Accountants' Report 6

Cantabio Pharmaceuticals Ltd

Company Information
for the year ended 30 June 2024







DIRECTOR: Dr G Toth





REGISTERED OFFICE: St. George's Court
Winnington Avenue
Northwich
Cheshire
CW8 4EE





REGISTERED NUMBER: 12965535 (England and Wales)





ACCOUNTANTS: Bennett Brooks & Co Limited
Chartered Accountants
St George's Court
Winnington Avenue
Northwich
Cheshire
CW8 4EE

Cantabio Pharmaceuticals Ltd (Registered number: 12965535)

Balance Sheet
30 June 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,345 523
Investments 5 6,313 6,313
7,658 6,836

CURRENT ASSETS
Debtors 6 549,958 244,705
Cash at bank 12,432 8,720
562,390 253,425
CREDITORS
Amounts falling due within one year 7 1,041,811 610,287
NET CURRENT LIABILITIES (479,421 ) (356,862 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(471,763

)

(350,026

)

CAPITAL AND RESERVES
Called up share capital 8 1,000 1,000
Retained earnings (472,763 ) (351,026 )
SHAREHOLDERS' FUNDS (471,763 ) (350,026 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 26 June 2025 and were signed by:





Dr G Toth - Director


Cantabio Pharmaceuticals Ltd (Registered number: 12965535)

Notes to the Financial Statements
for the year ended 30 June 2024

1. STATUTORY INFORMATION

Cantabio Pharmaceuticals Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The validity of this assumption depends on the continued support of the related parties. Having reviewed the future cash flows of the business, the directors are satisfied that the company will have adequate resources to meet its liabilities as they fall due. On this basis, the directors believe it appropriate to prepare the accounts on a going concern basis.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation. Cost includes the original purchase price of the asset and the costs attributable to bringing the asset to its working condition for its intended use.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows:

Computer equipment- 20% on cost
Fixtures and Fittings- 20% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Short term debtors and creditors
Short term debtors and creditors with no stated interest rate are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Cash and cash equivalents
Cash and cash equivalents includes cash in hand, cash held with banks and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Cantabio Pharmaceuticals Ltd (Registered number: 12965535)

Notes to the Financial Statements - continued
for the year ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Share capital
Ordinary shares are classed as equity.

Distributions to equity holders
Dividends are recognised as a liability in the financial statements in the period in which the dividends are approved by the company's shareholders. These amounts are recognised in the statement of changes in equity.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - 1 ).

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 July 2023 566
Additions 1,169
At 30 June 2024 1,735
DEPRECIATION
At 1 July 2023 43
Charge for year 347
At 30 June 2024 390
NET BOOK VALUE
At 30 June 2024 1,345
At 30 June 2023 523

5. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 July 2023
and 30 June 2024 6,313
NET BOOK VALUE
At 30 June 2024 6,313
At 30 June 2023 6,313

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed by group undertakings 529,958 224,705
Other debtors 20,000 20,000
549,958 244,705

Cantabio Pharmaceuticals Ltd (Registered number: 12965535)

Notes to the Financial Statements - continued
for the year ended 30 June 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed to group undertakings 1,032,584 606,087
Other creditors 9,227 4,200
1,041,811 610,287

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1,000,000 Ordinary 0.001 1,000 1,000

9. ULTIMATE PARENT COMPANY

Cantabio Pharmaceuticals Inc. is the ultimate parent company. The parent's registered office is 2225 East Bayshore Road, Palo Alto, United States CA 94303.

Chartered Accountants' Report to the Director
on the Unaudited Financial Statements of
Cantabio Pharmaceuticals Ltd

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Cantabio Pharmaceuticals Ltd for the year ended 30 June 2024 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Cantabio Pharmaceuticals Ltd in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Cantabio Pharmaceuticals Ltd and state those matters that we have agreed to state to the director of Cantabio Pharmaceuticals Ltd in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Cantabio Pharmaceuticals Ltd and its director for our work or for this report.

It is your duty to ensure that Cantabio Pharmaceuticals Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Cantabio Pharmaceuticals Ltd. You consider that Cantabio Pharmaceuticals Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Cantabio Pharmaceuticals Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Bennett Brooks & Co Limited
Chartered Accountants
St George's Court
Winnington Avenue
Northwich
Cheshire
CW8 4EE


26 June 2025